300. IgG4関連疾患
[臨床試験数:31,薬物数:33(DrugBank:16),標的遺伝子数:11,標的パスウェイ数:81

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000022633
2016/06/0606/06/2016Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis. autoimmune pancreatitisSteroid treatment (total 56 weeks)

Induction ~ 4 weeks : Prednisolone 10mg/day
4 weeks ~ 48 weeks : Prednisolone 5mg/day
48 weeks ~ 52 weeks : Prednisolone 2.5mg/day
52 weeks ~ 56 weeks : Prednisolone 1mg/day
Osaka UniversityNULLPending20years-oldNot applicableMale and Female20Not selectedJapan
2JPRN-UMIN000003804
2010/05/0125/06/2010Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitis autoimmune pancreatitisPrednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day.
Maintenance therapy at a dose of 5 mg/day is continued.
Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation.
Department of Gastroenterology, University of TokyoNULLRecruiting20years-oldNot applicableMale and Female20Not applicableJapan